Inherited defects in the gene for methylmalonyl-CoA mutase (EC 5.4.99.2) result in the mut forms of methylmalonic aciduria. mut°mutations lead to the absence of detectable mutase activity and are not corrected by excess cobalamin, whereas mutF mutations exhibit residual activity when exposed to excess cobalamin. Many of the mutations that cause methylmalonic aciduria in humans affect residues in the C-terminal region of the methylmalonyl-CoA mutase. This
when exposed to excess cobalamin. Many of the mutations that cause methylmalonic aciduria in humans affect residues in the C-terminal region of the methylmalonyl-CoA mutase. This portion of the methylmalonyl-CoA mutase sequence can be aligned with regions in other B12 (cobalamin)-dependent enzymes, including the C-terminal portion of the cobalaminbinding region of methionine synthase. The alignments allow the mutations of human methylmalonyl-CoA mutase to be mapped onto the structure of the cobalamin-binding fragment of methionine synthase from Escherichia coli (EC 2.1.1.13), which has recently been determined by x-ray crystallography. In this structure, the dimethylbenzimidazole ligand to the cobalt in free cobalamin has been displaced by a histidine ligand, and the dimethylbenzimidazole nucleotide "tail" is thrust into a deep hydrophobic pocket in the protein. Previously identified mut°and mutF mutations (Gly-623 -> Arg, Gly-626 -> Cys, and Gly-648 -* Asp) of the mutase are predicted to interfere with the structure and/or stability ofthe loop that carries His-627, the presumed lower axial ligand to the cobalt of adenosylcobalamin. Two mutants that lead to severe impairment (mut°) are Gly-630 -> Glu and Gly-703 -> Arg, which map to the binding site for the dimethylbenzimidazole nucleotide substituent of adenosylcobalamin. The substitution of larger residues for glycine is predicted to block the binding of adenosylcobalamin.
Methylmalonyl-CoA mutase (EC 5.4.99.2) is one of two cobalamin (B12)-dependent enzymes found in humans. This enzyme uses the adenosylcobalamin (AdoCbl) cofactor to catalyze the isomerization of methylmalonyl-CoA to succinylCoA, a reaction required in the catabolism of methionine, valine, threonine, isoleucine, odd-chain fatty acids, and cholesterol. Although the well-characterized bacterial methylmalonylCoA mutases are heterodimers with subunits ofMr 80,100 and Mr 69,500 (1, 2) , the human enzyme is a homodimer of Mr 78,489 subunits (3, 4) . Cloning and expression of the human mitochondrial enzyme has made it accessible for study (5, 6) and has facilitated the characterization of mutations (7) (8) (9) (10) (11) (12) (13) (14) .
Methylmalonic aciduria, an inborn error of metabolism that can arise from functional impairment of methylmalonyl-CoA mutase, is associated with infant mortality and with developmental retardation (15) . A survey of newborns in Massachusetts suggested that methylmalonic acidemia occurs in 1 in 48,000 births (16) . This number is considered a minimum estimate (17) . Patients with defects in methylmalonyl-CoA metabolism have elevated concentrations of methylmalonic acid in blood and urine and can suffer from extreme acidosis and die within the first few weeks of life (15) . Although methylmalonic aciduria can result from defects either in the apoenzyme or in cofactor transport and processing (15) (9, (18) (19) (20) . Enzymes in mut-fibroblasts typically show elevated apparent Kmll values for AdoCbl, suggesting some perturbation in the binding of the cofactor (11, 12, (18) (19) (20) . In contrast, high concentrations of AdoCbl are unable to restore the activity of mut°mutant proteins. In general, mut-patients have a milder phenotype than do mut°p atients (21) . Many of the mutations that cause methylmalonic aciduria in humans affect residues in the C-terminal region of the methylmalonyl-CoA mutase subunit. This portion of the protein sequence can be aligned ( Fig. 1) with the small subunit of glutamate synthase (MutS) (27, 34) , with the C terminus of methylene glutarate mutase (26) , and with the C-terminal portion of the cobalamin-binding region of methionine synthase (EC 2.1.1.13) (27, 33, 35) . The alignments allow us to map the mutations of human methylmalonyl-CoA mutase onto the structure of the cobalamin-binding fragment of methionine synthase from E. coli, which has recently been determined by x-ray crystallography (33) , and thus to make inferences about how mutations in human methylmalonyl-CoA mutase lead to dysfunction of the enzyme. 
Alignments of the sequences of methylmalonyl-CoA mutase with other B12-dependent mutases that catalyze carbon skeleton rearrangements and with the cobalamin-binding fragments of methionine synthase. The alignments are based on the structure of Escherichia coli methionine synthase. Residues that are invariant are noted in bold, and mutations of human methylmalonyl-CoA mutase that occur within the aligned regions have been indicated by arrows; the corresponding residue numbers in methionine synthase are given in parentheses. Aligned sequences are residues 610-750 of the human methylmalonyl-CoA mutase, designated mcm_Hum (22) ; residues 610-750 of mouse methylmalonylCoA mutase, designated mcm_Mou (23); residues 593-728 of the MutB subunit from Propionibacterium shermanii, designated mcm Ps (1); residues 596-733 of the MutB subunit from Streptomyces cinnamonensis, designated mcm Sc (24); residues 601-744 of the deduced amino acid sequence of an open reading frame from Caenorhabditis elegans, designated mcm Ce (GenBank accession no. Z35604; deposited by B. Mortimore in 1995); and residues 580-714 of an open reading frame (sbm) from E. coli with homology to methylmalonyl-CoA mutase, designated mcm Ec (25) . Also shown are residues 468-614 of methyleneglutarate mutase, designated mgm Cb (26); sequences of the small subunit of glutamate mutase from Clostridium tetanomorphum, designated gm_Ct (27) ; and sequences from Clostridium cochlearium, designated gmnCc (28) . The final four lines give cobalamin-dependent methionine synthase sequences: residues 742-896 of E. coli, designated ms Ec (29-31); residues 758-916 of an open reading frame from C elegans, designated ms_Ce (GenBank accession no. Z46828; deposited by J. Swinburne in 1995); residues 131-290 of the deduced amino acid sequence from Haemophilus influenzae Rd, designated ms_Hi (32); and residues 714-867 of the deduced amino acid sequence of an open reading frame metH2 from Mycobactenum leprae, designated ms_Ml (GenBank accession no. U00017; deposited by D. R. Smith in 1994). The numbering scheme for the human methylmalonyl-CoA mutase amino acid sequence shown here is that introduced by Andrews and coworkers (22) . The secondary structure elements indicated below the aligned sequences are derived from the x-ray crystallographic analysis of the cobalaminbinding region of methionine synthase from E. coli (33) .
651-896 of the 1227-residue chain. The N-terminal portion of the resulting "open" conformation of the bound methylcobalthe fragment is an a-helical domain that interacts with the amin and the extensive areas of contact between the cofactor upper (,3) face of the bound methylcobalamin cofactor, where and the a/,B domain. The dissociated dimethylbenzimidazole the methyl group is coordinated, whereas the 150 residues of nucleotide is inserted into a deep pocket that penetrates to the the C-terminal part of the fragment, as depicted in Fig. 2 Table 1 ) are indicated by enlarged Ca atoms and are labeled with the corresponding residue numbers from methionine synthase. aligned in Fig. 1 , and includes invariant residues located in regions that interact directly with cobalamin in methionine synthase (33, 35) . Conservation of these sequences has suggested that the proteins included in Fig. 1 all bind cobalamin similarly, an idea that is supported by electron paramagnetic resonance spectroscopy. In experiments similar to that described by Stupperich and coworkers (36) , it has been shown that histidine interacts with cobalt in methylmalonyl-CoA mutase from P. shermanii (37) and in glutamate mutase from Cl. cochlearium (38) . Table 1 lists the mutations of human methylmalonyl-CoA mutase that are located in the region homologous to the a/P domain of methionine synthase. The positions of these mutations in the sequence and in the structure of the cobalamin-binding fragment are shown in Figs. 1 and 2, respectively. Fig. 2 indicates that many of the known mutations are clustered in the vicinity of the bound cobalamin (11) .
Mutations That Block the Nucleotide Binding Pocket. Replacement of glycines at positions 630 and 703 of human methylmalonyl-CoA mutase results in the more severe mut°p henotypes (11, 14) . Unlike the mut-mutations, these mutations result in an enzyme whose activity cannot be even partially restored with increased amounts of AdoCbl. Although this phenotype could arise for other reasons, such as mutation of an essential catalytic residue, the structure Gly-630 and Gly-703 (Gly-762 and Gly-834 in methionine synthase) are invariant residues in the sequence motif for cobalamin binding (Fig. 1 ). Mutations at these positions replace conserved glycines in the site that binds the dimethylbenzimidazole nucleotide in methionine synthase. As shown in Figs. 2 and 3 , the nucleotide substituent is accommodated in a long pocket between two of the (3-sheet strands and two helices. Comparison of the a/f3 domain of methionine synthase with the nucleotide-binding domain of lactate dehydrogenase reveals that the helices are not pried away from the 3-sheet to make room for the cobalamin nucleotide tail, but rather glycines are substituted for residues with larger side chains (35) . Thus, replacement of conserved glycines with bulky residues would be predicted to interfere with binding of AdoCbl to methylmalonyl-CoA mutase by occluding the tailbinding pocket. To explore the structural consequences of these mutations, the mutant side chains were modeled using interactive graphics, and the structures were subjected to energy minimization in X-PLOR 3.1 (40) . The results, shown in Fig. 3 , indicate that the dimethylbenzimidazole-binding pocket would be blocked by either of these mutations, consistent with the observation that excess AdoCbl does not restore activity. Both mutations are easily accommodated in the empty pocket, suggesting that the mutant apoproteins can fold correctly, as expected from their activity in complementation experiments (14) . The models further imply that enzymatic activity might be restored by using modified cobalamins as cofactors.
Mutant Methylmalonyl-CoA Mutases with Blocked Nucleotide Pockets May Bind Cofactors with Truncated Side Chains. As shown in Fig. 3 , modifying the cobalamin to fit the mutant proteins offers a potential route to the formation of molecules that are competent catalysts. Modeling using the structure of the a/13 domain of methionine synthase suggests that a cobalamin whose tail is truncated before the phosphate group (cobinamide) would be able to bind to the Gly-630 -> Glu mutant protein (Fig. 3B) , whereas truncating the tail after the phosphate may restore binding to the Gly-703 -Arg mutant protein (Fig. 3C) . AdoCbl analogs, including adenosylcobinamide, have been shown to bind relatively tightly to methylmalonyl-CoA mutases (37, 41, 42) , and it is conceivable that the cobalamin analogs displayed in Fig. 3 might in fact bind better to mutant protein than to wild-type protein. For example, the side chain of Glu-630 could potentially hydrogen bond to the terminal hydroxyl group of the truncated cobalamin, increasing affinity for the analog, and interactions between the positively charged Arg-703 side chain and the negatively charged cobalamin phosphate could similarly enhance the affinity for the cobalamin analog.
Mutations Affecting the "Histidine Loop" Lead to Impaired Function. The most surprising aspect of the structure of the cobalamin-binding domains of methionine was the replacement of the dimethylbenzimidazole ligand to cobalt by a histidine from the protein. The loop that contributes the histidine ligand adopts an unusual conformation, and comparison with structures of other nucleotide-binding proteins suggests that it may be unique to Rossmann folds that bind cobalamin. Interactions between the histidine loop and the cobalamin are extensive (Fig. 4) and are expected to be important both for catalysis and for binding of the cofactor. It is perhaps no surprise that mutations in and around this loop lead to dysfunction. Two mutations that cause methylmalonic aciduria in humans, Gly-623 --Arg and Gly-626 -> Cys, directly affect residues in the loop (11, 14) . Gly-623 of methylmalonyl-CoA mutase corresponds to Lys-755 in methionine synthase, which is in the second position of a 13-turn. Glycines are often found in (3-turns for steric reasons (43) . In all of the mutase sequences listed in Fig. 1 , glycine occurs in position 2 of the putative (3-turn, and in all the methyltransferase sequences, glycine is found in position 3. We suspect that accommodation to the arginine side chain in the Gly-623 -, Arg mutant may induce deleterious changes in the conformation of the loop carrying the histidine ligand and may, in addition, affect interactions of the a/13 domain with other domains of the enzyme.
The Gly-626 -> Cys mutation at the residue between aspartate and histidine in the Asp-Xaa-His-(Xaa)2-Gly motif decreases the enzymatic activity, resulting in a mut-phenotype (11) . Comparison of sequences would not predict a major effect of this substitution. Valine, with a similar volume to cysteine, is found in this location in methionine synthase, and cysteine occurs at this position in the glutamate mutases. Why then is the activity of the enzyme so affected? Although this mutation appears conservative, the residue is positioned in a critical place in the structure. In methionine synthase, the backbone nitrogen of this residue directly contacts the cobalamin. Thus, even a conservative change at this location may affect interactions at the lower face of the corrin.
A third mutation, Gly-648 --Asp, replaces the glycine residue that aligns with Gly-781 in methionine synthase and displays a mut-phenotype (11) . This residue is not in direct contact with the cobalamin but makes interactions that stabilize the loop carrying the histidine ligand. In methionine synthase, Gly-781 is located in a ,B-bulge at the C terminus of strand ,311. As can be seen in Fig. 5 , a series of backbone hydrogen bonds from the 1311-alI connector helps to position the histidine loop. Two ways in which a mutation at Gly-648 could affect the structure and cobalamin affinity of methylmalonyl-CoA mutase are suggested by the related structure of methionine synthase (Fig. 5) . First, the bulge glycine adopts a backbone conformation that would be high energy for any other residue. If substitution of the glycine disrupts the Ledley (11, 12, 14, 44) have established that a point mutation at the N terminus of the protein subunit that leads to complete abolition of activity in a homozygote, Arg-93 His, can be complemented by any one of a cluster of mutations in the C terminus of the subunit that themselves abolish activity. These observations led Crane and Ledley (11) to suggest that the C-terminal portion of human methylmalonylCoA mutase was critical for cobalamin binding and could be complemented in trans by the N-terminal portion of another subunit (Fig. 6 ). This idea can be rationalized in view of the structure of the cobalamin-binding fragment of methionine synthase. As shown in Fig. 2 , the cobalamin in methionine synthase is sandwiched between the a-helical region contacting the top face of the cobalamin and a Rossmann fold interacting with the lower face of the cobalamin and the nucleotide side chain. These two domains are connected by a single peptide bridge that appears disordered in the crystal structure, indicating conformational flexibility. The structure suggests that the interallelic complementation arises because the AdoCbl prosthetic group of human methylmalonyl-CoA mutase can be bound by the C terminus of one subunit, which interacts with the bottom face of cobalamin and with the nucleotide tail, and also interacts, in the vicinity of the top face, with the N terminus of the other subunit. Since the bacterial methylmalonyl-CoA mutases are heterodimers of chains with distinctly different sequences, and only one chain shows clear homology with the cobalamin-binding region of methionine synthase, the forthcoming structure of the dimeric bacterial methylmalonyl-CoA mutase from P. shermanii (2, 47) (48) showed that analogs that stimulate methionine synthase activity in vitro can inhibit activity in vivo. They suggested that the in vivo inhibition by analogs may be due to inhibition of intracellular cobalamin transport or to inhibition of one of the enzymes involved in cobalamin processing (48) . We know that intrinsic factor, the protein responsible for cobalamin absorption in the small intestine, has a much higher specificity for cobalamin than it does for analogs (49) , whereas transcobalamin II, the major plasma transport protein for cobalamin, is less selective and can bind analogs with high affinity (48) . Unfortunately, cobinamide, the analog displayed in Fig. 3B (45, 46) . Mixing together molecules homozygous for a mutation (X) in the N terminus with molecules homozygous for a mutation (X) in the C terminus will theoretically result in 50% heterozygous molecules (Lower, Center), which will have one doubly mutated active site and one normal active site. Note. A paper by Mancia and coworkers (50) 
